Last reviewed · How we verify
Topical Prednisolone
Topical Prednisolone is a Topical corticosteroid Small molecule drug developed by Patrick R. Oellers, MD. It is currently FDA-approved for Inflammatory and pruritic dermatoses (eczema, psoriasis, contact dermatitis), Allergic conjunctivitis and other inflammatory ocular conditions.
Topical prednisolone is a corticosteroid that suppresses local inflammatory and immune responses in the skin and eyes by binding to glucocorticoid receptors.
Topical prednisolone is used to treat various conditions, including eye inflammation, allergic conjunctivitis, and evaporative dry eye, as indicated by ClinicalTrials.gov. It is a corticosteroid, a type of steroid hormone, used to treat inflammatory conditions, as stated on Wikipedia.
At a glance
| Generic name | Topical Prednisolone |
|---|---|
| Sponsor | Patrick R. Oellers, MD |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology, Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Prednisolone is a synthetic glucocorticoid that penetrates skin or ocular tissue and binds intracellular glucocorticoid receptors, leading to suppression of pro-inflammatory cytokine production, reduced immune cell infiltration, and decreased vasodilation and edema. When applied topically, it provides localized anti-inflammatory effects with reduced systemic absorption compared to oral formulations.
Approved indications
- Inflammatory and pruritic dermatoses (eczema, psoriasis, contact dermatitis)
- Allergic conjunctivitis and other inflammatory ocular conditions
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Ocular irritation (if ophthalmic formulation)
- Secondary infection
Key clinical trials
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Oral Prednisolone Versus Posterior Sub-Tenon Triamcinolone for Acute Ocular VKH
- Dextenza in the Post-op Management of Vitreoretinal Surgeries (PHASE4)
- Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression (PHASE3)
- The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery) (PHASE4)
- A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical Prednisolone CI brief — competitive landscape report
- Topical Prednisolone updates RSS · CI watch RSS
- Patrick R. Oellers, MD portfolio CI
Frequently asked questions about Topical Prednisolone
What is Topical Prednisolone?
How does Topical Prednisolone work?
What is Topical Prednisolone used for?
Who makes Topical Prednisolone?
What drug class is Topical Prednisolone in?
What development phase is Topical Prednisolone in?
What are the side effects of Topical Prednisolone?
What does Topical Prednisolone target?
Related
- Drug class: All Topical corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: Patrick R. Oellers, MD — full pipeline
- Therapeutic area: All drugs in Dermatology, Ophthalmology
- Indication: Drugs for Inflammatory and pruritic dermatoses (eczema, psoriasis, contact dermatitis)
- Indication: Drugs for Allergic conjunctivitis and other inflammatory ocular conditions
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing